Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Interest Income
Income earned on cash, deposits, and investments held by the company.
Citius Oncology, Inc.NASDAQ: CTOR
Interest Income · Q2 FY2026 · quarter ended Mar 2026
Interest income remains negative
Q2 FY2026 interest income was $43.72K, compared with $0 a year earlier. Trailing-twelve-month interest income was $72.01K.
Context
- Interest income increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly interest income holds near $43.72K or moves back toward the trailing-twelve-month quarterly average of $18K.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 36.37K USD
- Year-over-year change
- —
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 36.37K | — |
| FY2024 | 2024-09-30 | 0 | — |
| FY2023 | 2023-09-30 | 0 | — |
| FY2022 | 2022-09-30 | 0 | — |
Interest Income vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's LTM Mar 2026 interest income of $72.01K is the 6th highest of the 10 companies compared; the peer median is $319.36K.
- Interest income amounts to 1.3% of revenue for CTOR, versus a peer median of 1.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $9.58M | -41.8% | +23.7% | 151.7% | |
| LTM Mar 2026 | $9M | +153.2% | +64.3% | — | |
| LTM Mar 2026 | $1.98M | -53.6% | +31.4% | 3.6% | |
| LTM Mar 2026 | $1.93M | -34.2% | -10.0% | 168.6% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $319.36K | +22.3% | +120.0% | — |
CTORCitius Oncology, Inc. | LTM Mar 2026 | $72.01K | — | — | 1.3% |
| LTM Mar 2026 | $64K | -36.6% | +74.9% | 0.1% | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CTOR) | $319.36K | -39.2% | +47.9% | 1.9% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 6.86M | 4.24M | 4.93M | 6.42M |
| Selling, General & Admin | 2.86M | 7.88M | 15.65M | 17.1M |
| Operating Expenses | 9.71M | 12.12M | 20.57M | 23.52M |
| Depreciation & Amortization | 9.71M | 0 | 0 | 0 |
| EBITDA | 0 | (12.12M) | (20.57M) | (23.49M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (9.71M) | (12.12M) | (20.57M) | (23.52M) |
| Operating Margin | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 36.37K |
| Interest Expense | 0 | 0 | 0 | 218.03K |
| Other Income / Expenses | 0 | 0 | 0 | (181.66K) |
| Income Before Tax | (9.71M) | (12.12M) | (20.57M) | (23.7M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 1.15M | 576K | 576K | 1.06M |
| Net Income | (10.87M) | (12.7M) | (21.15M) | (24.76M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.08) | (0.19) | (0.30) | (0.34) |
| EPS (Diluted) | (0.08) | (0.19) | (0.30) | (0.34) |
| Weighted Avg Shares | 90.16M | 89.48M | 71.55M | 73.27M |
| Weighted Avg Shares (Diluted) | 90.16M | 89.48M | 71.55M | 73.27M |
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.